10BagR, I believe Don spelled out what will potentially take place going forward if we ignore Option #2 and #3. That leaves the more detailed Option #1.

"Option 1, Resverlogix will now finalize its ongoing negotiations with Major Pharmaceutical companies to determine a suitable partner for co-developing apabetalone. Co-development discussions include the following: ▪ Resverlogix will receive a significant upfront payment H2, 2020. ▪ The Phase 3b clinical trial will be funded by the partnering company - $120 to $150 MM USD. ▪ Our new partner can supply their SGLT2 diabetes drug as the co-medication. Thus providing the pharma partner with valuable marketing material and the ability to launch a fixed-dose combination product with patent coverage until 2040. ▪ The deal will also include substantial milestone and royalty payments with an M&A right of first refusal option"

I am paying attention to "M&A right of first refusal option".

To play it fair with our largest shareholder, Shenzhen Hepalink, I can see an "M&A right of first refusal option" play out between HL and a third-party equity BP partner. The third-party BP partner will provide the necessary funds for business operations and BOM2.